Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05011162 · ClinicalTrials.gov registry record · NA
"REACT-FM" Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia
A NA study, sponsored by Swing Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT05011162 is a NA study that has completed, run by Swing Therapeutics. The registered enrollment target is 130 participants.
The verdict
NCT05011162, a NA study, has completed, sponsored by Swing Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
The objective of this study is to assess the clinical impact of a digital therapy for the management of fibromyalgia. Study participants receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia. The primary endpoint is the Patient Global Impression of Change (PGIC) at week 12. This is a virtual, single-arm, pragmatic, non-significant risk study.
Interventions
- DEVICE Digital ACT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-07-25 |
| Est. Completion | 2024-03-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05011162
The ClinicalTrials.gov registry entry for NCT05011162 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swing Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Digital ACT is the first listed.
NCT05011162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05011162 about?
NCT05011162 is a clinical study titled ""REACT-FM" Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia". The objective of this study is to assess the clinical impact of a digital therapy for the management of fibromyalgia. Study participants receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia. The primary endpoint is the Patient Global...
What is the current status of trial NCT05011162?
This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2021-07-25. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT05011162?
The interventions under investigation include: Digital ACT (DEVICE).
Who is sponsoring clinical trial NCT05011162?
This trial is sponsored by Swing Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.